SEHK:9966Biotechs
Assessing Alphamab Oncology (SEHK:9966) Valuation After JSKN003 Phase III Trial Patient Dosing Milestone
Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate following its Breakthrough Therapy Designation in China.
See our latest analysis for Alphamab Oncology.
The JSKN003 milestone comes after a mixed run in the shares, with a 1-year total shareholder return of 124.81% contrasting with a 30-day share price return decline of 12.74% and longer term 3 and 5...